Public companies seeking outside funding for a late-stage trial have several avenues open to them – find a partner, offer more shares or seek a private investment in public equity (PIPE) deal. But what if neither partners nor investors bite? The next best thing might be to take out a loan.
Key Takeaways
- Arcus Biosciences has obtained a loan worth up to $250m from Hercules Capital to fund Phase III development of its HIF-2a inhibitor casdatifan.
- Data from a Phase I/II trial of the product in renal cell carcinoma should come later this year
That seems likely to have been Arcus Biosciences, Inc.’ reasoning behind the deal it has done with Hercules Capital, obtaining a loan worth up to $250m to fund Phase III development of its HIF-2a inhibitor casdatifan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?